Inhibition Activity of Herpes Virus (HSV) Replication by Α-Tif Sirna-Loaded PLGA-TPGS Nanoparticles in Vitro and in Vivo

Kebing Wang,Chengming Yang,Jiajun Ye,Fanqi Zeng,Yanling Duan,Yi Zheng,Bo Hu,Xilan Yu
DOI: https://doi.org/10.1166/jbn.2017.2378
2017-01-01
Journal of Biomedical Nanotechnology
Abstract:Background: Herpes simplex viruses are important pathogens that cause several diseases. Alpha-gene trans-inducing factor (alpha-TIF) is critical for HSV replication and assembly, and silencing alpha-TIF inhibits HSV replication. Objective: This study aimed to investigate the inhibitory effect of alpha-TIF siRNA-loaded PLGA-TPGS nanoparticles on HSV replication in vitro and in vivo. Methods: We have developed novel biodegradable PLGA-TPGS nanoparticles (NPs) as a system to deliver small interfering ribonucleic acid (siRNA) targeting alpha-TIF to inhibit HSV. We characterized their features including particle size, zeta potential, envelopment efficiency (EE) and in vitro release of alpha-TIF siRNA. Meanwhile, the cytotoxicity of alpha-TIF siRNA-loaded PLGA-TPGS nanoparticles on primary keratinocytes and HeLa cells was measured by MTT assay. The inhibitory effect of these nanoparticles on HSV1 replication was analyzed using plaque formation assay in vitro, and the nanoparticles protected mice against vaginal infection from a lethal dose of HSV2. Results: The size of PLGA-TPGS/alpha-TIF-siRNA NPs was 207.0+/-2.94 nm and their zeta potential was-31.25+/-1.70 mV. The in vitro release of NPs displayed bi-phasic kinetics: it was released up to 54.2% and 51.2% at pH 5.0 and pH 7.4, respectively, within 96 hours, followed by a slower release. PLGA-TPGS/alpha-TIF-siRNA NPs had no toxicity on primary keratinocytes and HeLa cells. The release of siRNA located in NPs was studied using fluorescent microscopy. PLGA-TPGS/alpha-TIF-siRNA NPs inhibited HSV1 replication much more efficiently than control groups. In vivo animal experiments showed that PLGA-TPGS/alpha-TIF-siRNA NPs could significantly prolong the survival time of mice and have little cytotoxicity compared with controls including the alpha-TIF siRNA lipofectamine complex. Conclusions: PLGA-TPGS nanoparticles serve as a good siRNA carrier and alpha-TIF siRNA-loaded PLGA-TPGS nanoparticles serve as a potential candidate for HSV infection-associated diseases.
What problem does this paper attempt to address?